

**ISEC HEALTHCARE LTD.**  
(Company Registration No. 201400185H)  
(Incorporated in Singapore on 2 January 2014)  
(the “**Company**”)

---

**UPDATE ANNOUNCEMENT –  
NOTIFICATION FROM CERTAIN SHAREHOLDERS OF THE COMPANY**

---

The Board of Directors (the “**Board**”) of the Company refers to the announcement released by the Company on 2 July 2019 (the “**July 2019 Announcement**”).

*Capitalised terms used herein, but not otherwise defined, shall have the meanings ascribed to them in the July 2019 Announcement.*

Further to the July 2019 Announcement, the Board wishes to update Shareholders that it understands from Dr Wong Jun Shyan (Executive Director and Chief Executive Officer of the Company), one of the Notifying Shareholders, that the Notifying Shareholders remain at an advanced stage of negotiations with a third party purchaser independent of the Notifying Shareholders for the sale of **part** of their shares of the Company (the “**Potential Transaction**”) and that based on the current proposed terms, the Potential Transaction, if completed, is likely to lead to an offer for the shares of the Company (the “**Offer**”) in due course. To date, no definitive sale and purchase agreement has been entered into in respect of the Potential Transaction.

The Company will, in compliance with applicable rules (including the Corporate Disclosure Policy under Section B: Rules of Catalist of the Listing Manual of the Singapore Exchange Securities Trading Limited and the Singapore Code on Take-overs and Mergers), make the relevant disclosures (if required) at the appropriate time.

**There is no certainty that any definitive sale and purchase agreement will be entered into in respect of the Potential Transaction. If any definitive sale and purchase agreement is entered into, such agreement may also be conditional in nature and there is no assurance that any Potential Transaction will be completed or that an Offer will be made in due course. Shareholders and potential investors are advised to exercise caution in dealing in the shares of the Company and to refrain from taking any action which may be prejudicial to their interests. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt as to the action that they should take.**

The Directors of the Company (including any who may have delegated detailed supervision of this announcement) have taken all reasonable care to ensure that the facts stated and all opinions expressed in this announcement are fair and accurate and that no material facts have been omitted from this announcement, and they jointly and severally accept responsibility accordingly.

By Order of the Board

Sitoh Yih Pin  
Non-Executive Chairman and Independent Director  
2 August 2019

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”) in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalist.*

*This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms. Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and Email: sponsorship@ppcf.com.sg).*